Search bioRxiv⌕ Search

bioRxiv · 10.1101/2022.07.18.500490

RMeDPower for Biology: guiding design, experimental structure and analyses of repeated measures data for biological studies

Abstract

Lack of experimental reproducibility has plagued efforts to understand biology at both basic biomedical and preclinical levels. The cause is often improperly powered experiments and the use of inadequate statistical tools. To overcome these problems, we developed RMeDPower2, a complete, user-friendly package of tools in R that will allow scientists that are not deeply familiar with statistical analyses to predict the scope and size of biological data they need when conducting experiments with a repeated measures design. RMeDPower2 is based on Generalized Linear Mixed Effects Models (GLMM), which are better suited to the statistical analysis of these experiments than ANOVA or t-tests. We illustrate the use of RMeDPower2 and compare it to t- test for power calculations, using our own pilot studies of iPSC-derived motor neurons (iMNs) from sporadic ALS (sALS) patients versus healthy controls. We report that sALS iMNs display reduced numbers of soma- emanating processes compared to control iMNs using RMeDPower2. We expect RMeDPower2 to find applications far beyond cell assays, from single-cell RNAseq experiments to brain slice electrophysiology or animal behavior. MotivationThe lack of rigor and reproducibility in biomedical research has caused a crisis that has been highlighted in the popular literature and has become a focus for the National Institutes of Health1-3. It has been estimated that the majority of published empirical observations cannot be reproduced4-9, rendering nearly futile any effort to build on these observations to further our understanding of basic biological mechanisms or design effective therapeutic approaches. Further, the resources and time spent attempting to reproduce findings from low-quality or incorrectly acquired data are estimated to cost the global scientific community about 200 billion dollars per year10. The root cause lies in experimental designs that are not structured or powered adequately for conclusive statistical analyses. Since all biomedical researchers cannot be expected to have a deep knowledge of statistics or easy access to trained statisticians, tools are desperately needed to help them check the design of their experiments and apply adequate statistical power estimation. Not only could this improve our confidence in scientific outcomes, it could help make biological experiments more time-efficient and cost-effective. For example, if a researcher could estimate how many experiments should be performed and how many cell lines, animals or tissue samples should be collected to achieve sufficient statistical power to test their hypothesis, they may adjust their experimental design to fit their time or budgetary constraints without jeopardizing the quality of their findings. Another source of scientific errors comes from technologies such as scRNA-seq, whose advances are leading to a rapid increase in studies involving so-called "pseudo-replication", which treats non-independent measures as if they were independent. For example, carrying out multiple measurements on a single sample instead of using separate, independent samples would represent non-independent replication. The risk of pseudo-replication11 (illustrated further below), can be remedied by the implementation of rigorous statistical methods that apply to all aspects of the data arising from such designs.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Shin, M.-G., Kaye, J. A., Amirani, N., Lam, S., Thomas, R., Finkbeiner, S.. 2022-07-19. RMeDPower for Biology: guiding design, experimental structure and analyses of repeated measures data for biological studies. https://doi.org/10.1101/2022.07.18.500490

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Sequence context and partner availability specify divergent cell fates from a single transcription factor

Transcription factors drive the gene regulatory networks that control developmental transitions, yet which of their many targets a cell uses remains unresolved. Expressing Cebp, Cebp{beta} or Cebp{delta} identically, alone or with Oct4, Sox2, Klf4 and cMyc, gave four outcomes: adipocyte from fibroblasts and neural stem cells, trophectoderm from embryonic stem cells, and myeloid from B cells. Raising Cebp levels changed how many sites it reached, not which sequence it read: clustered motifs maintained somatic enhancers, while spillover onto low-copy sites created de novo enhancers carrying composites of Cebp and cell-type-restricted partners. In fibroblasts, Cebp also redistributed Oct4, Sox2 and Klf4 from early targets, blocking iPSC formation. Supplying the predicted partners rewrote the output: Spi1 redirected Cebp into parallel adipogenic and myeloid programs, via a transient PpargCD45 state using separate enhancers for each; TFAP2C abolished adipogenic conversion. Motif density and partner composites therefore assemble a factor's instructive output in the receiving cell.

cell biology↗

High-content screening identifies FDA-approved activators of mitophagy

Mitochondrial diseases are highly heterogeneous disorders caused by defects in oxidative phosphorylation, for which only limited therapeutic options are available. The elimination of dysfunctional mitochondria via mitophagy activation is an attractive strategy to treat several mitochondrial diseases, irrespective of the underlying genetic defect. To identify pharmacological activators of this pathway, we performed a high-content screening of 1,971 FDA-approved compounds using cellular reporters of TFEB nuclear translocation and mitophagy. This screening identified 294 compounds that promoted TFEB translocation, nine of which increased the number of mitolysosomes without compromising cell viability or damaging mitochondria. Among the selected compounds, Meptazinol and Ponatinib emerged as the top-ranked mitophagy inducers in fibroblasts from patients with complex I and IV deficiency, respectively, and were prioritised for further characterisation. However, they did not rescue the bioenergetic defect, suggesting that the stimulation of mitophagy per se is not sufficient to ameliorate the OXPHOS defect in mitochondrial diseases. Overall, our findings establish a scalable platform for the identification of pharmacological activators of TFEB and identify candidate compounds for therapeutic modulation of mitophagy.

cell biology↗

Matrix Gla Protein deficiency reveals a previously unrecognized mucosal calcification in the mouse airways

Tracheal calcification is a common finding that is considered to have limited clinical significance when detected most often in elderly individuals. Despite its frequent occurrence, the cellular and molecular mechanisms at the origin of tracheal calcification remain largely unexplored. In this context, we aimed to characterize the development of tracheal calcification, and to determine the role of matrix Gla protein (MGP), a major inhibitor of ectopic calcification whose genetic or pharmacologic deficiency is associated with premature tracheal calcification in humans. We found that wild-type mice undergo an unexpected early physiologic calcification of the tracheal cartilage rings beginning around one month after birth. This calcification progresses in a dynamic rostro-caudal sequence through a process involving terminal differentiation of tracheal chondrocytes. These findings challenge the prevailing view that tracheal cartilage is a permanent hyaline cartilage and instead reveals an early and highly organized physiologic calcification process. Furthermore, our findings further identify MGP as a key regulator of calcification within the respiratory tract. Indeed, MGP deficiency not only markedly accelerates tracheal cartilage calcification through a similar pattern and mechanism but also induces a previously unrecognized calcification of the tracheal mucosa, a lesion absent in wild-type mice. These alterations could partly explain the respiratory manifestations observed in MGP-deficient patients having Keutel syndrome, which include dyspnea, cough, stridor, and recurrent infections, symptoms previously being mainly attributed to calcification of the tracheal cartilage rings.

cell biology↗